Methods related to immunostimulatory nucleic acid-induced interferon
Methods and compositions are provided for extending the clinical utility of IFN-α in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-α treatment and reduce IFN-α treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs.
1. A chimeric nucleic acid comprising at least two immunostimulatory nucleic acids selected from the group consisting of CpG nucleic acids, T-rich nucleic acids, and poly-G nucleic acids, wherein at least one of the at least two immunostimulatory nucleic acids induces production of interferon alpha (IFN-α) from human peripheral blood mononuclear cells and has the sequence set forth by
ggGGGACGATCGTCgggggG (SEQ ID NO:7),
wherein each lower case letter represents phosphorothioate linkage and each upper case letter indicates a phosphodiester linkage, and wherein at least one immunostimulatory nucleic acid is an oligonucleotide comprising a diol at either or both termini.
2. The chimeric nucleic acid of claim 1 , wherein the diol is hexaethyleneglycol (HEG).
3. The chimeric nucleic acid of claim 1 , wherein the diol is tetraethyleneglycol (TEG).
4. The chimeric nucleic acid of claim 1 , wherein the chimeric nucleic acid induces production of type I IFN from human peripheral blood mononuclear cells but has minimal effects activating B cells.
5. A composition comprising the chimeric nucleic acid of claim 4 and a pharmaceutically acceptable excipient.
6. The composition of claim 5 , further comprising an antigen.
7. The composition of claim 5 , further comprising a microsphere.
8. A method of inducing an immune response in a subject, the method comprising administering to the subject a chimeric nucleic acid of claim 1 in an amount sufficient to induce an immune response in the subject.
9. A method of inducing an immune response in a subject, the method comprising administering to the subject a chimeric nucleic acid of claim 4 in an amount sufficient to induce an immune response in the subject.